Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Aug 03, 2018 12:25pm
138 Views
Post# 28410918

RE:RE:RE:7/20 Taimed QA

RE:RE:RE:7/20 Taimed QA
Pawscari wrote: Hi poor opinion 

this is transcriped from audio recordings by a website. And I’ve listened the recordings of two meetings so I can confirm this is correct 

1 yes they only confirm TH’s update. CFO mentioned before that anything regarding to sales will leave to TH to reply. He even suggest people to check TH’s website update, say it is helpful lol

2 it is new prescriptions. The 60-70 are EAP patients.

3 skip means he says a lot but those are not informative so I skip them 


Sorry if this sounds like I doubt you but I'm grateful you bring this info to the board.  ........ but if what they say is they leave it to thera to update on sales and then they immediately say new prescriptions are 29 then they've contradicted themselves straight off. Are you clear the 29 isnt said in the context of the trial/EAP patients?

SPCEO if next time you speak with Luc you could ask how many patients are still on the EAP it might be something Luc is prepared to share and clear up any possible confusion.

Again Pawscari apologies, my scepticism comes from not being able to read this myself rather than doubting your integrity.
Bullboard Posts